Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: Potential role of mcl-1 and FAK

Molecular Carcinogenesis

Volumn 52, Issue 11, 2013, Pages 879-889

  Guo, Xiao ^a   Yin, Shutao ^a   Dong, Yinhui ^a   Fan, Lihong ^a   Ye, Min ^b   Lu, Junxuan ^c   Hu, Hongbo ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Apoptosis; Curcumin; FAK; Mcl 1; Methylseleninic acid

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; BETA ACTIN; CURCUMIN; FOCAL ADHESION KINASE; LIPOCORTIN 5; METHYLSELENINIC ACID; PHOSPHATIDYLSERINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; FOCAL ADHESION KINASE 1; MCL1 PROTEIN, HUMAN; METHYLSELENIC ACID; MYELOID LEUKEMIA FACTOR 1; ORGANOSELENIUM DERIVATIVE; PTK2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; MALE; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CURCUMIN; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; MALE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; UP-REGULATION;

EID: 84886299613     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21933     Document Type: Article

References (42)

1. Amin AR, Wang D, Zhang H, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: Potential role of p53. J Biol Chem 2010; 285:34557-34565.
2. Khor TO, Keum YS, Lin W, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 2006; 66:613-621.
3. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31:2273-2289.
4. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276:1957-1963.
5. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 1998; 81:730-734.
6. Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 1997; 56:117-124.
7. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166:2034-2038.
8. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004; 96:696-703.
9. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
10. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998; 128:1845-1854.
11. Lu J, Jiang C. Selenium and cancer chemoprevention: Hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Sign 2005; 7:1715-1727.
12. Li GX, Lee HJ, Wang Z, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008; 29:1005-1012.
13. Wang L, Bonorden MJ, Li GX, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2009; 2:484-495.
14. Thomasset SC, Berry DP, Garcea G, et al. Dietary polyphenolic phytochemicals-Promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 2007; 120:451-458.
15. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008; 76:1340-1351.
16. Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 2007; 3:635-637.
17. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269:199-225.
18. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability and clinical trials. Arch Pharm (Weinheim) 2010; 343:489-499.
19. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39:283-299.
20. Li R, Qiao X, Li Q, et al., Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:2751-2758.
21. Chou T-C, Talalay P. Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
22. Bhat UG, Pandit B, Gartel AL. ARC synergizes with ABT-737 to induce apoptosis in human cancer cells. Mol Cancer Ther 2010; 9:1688-1696.
23. Hu H, Jiang C, Schuster T, Li GX, Daniel PT, Lü J. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther 2006; 5:1873-1882.
24. Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing factor (AIF): A phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 1999; 6:516-524.
25. Scharstuhl A, Mutsaers HA, Pennings SW, Russel FG, Wagener FA. Involvement of VDAC, Bax and ceramides in the efflux of AIF from mitochondria during curcumin-induced apoptosis. PLoS ONE 2009; 4:e6688.
26. Hilchie AL, Furlong SJ, Sutton K, et al. Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr Cancer 2010; 62:379-389.
27. Yin S, Dong Y, Li J, et al. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Apoptosis 2012; 17:388-399.
28. Frame MC, Patel H, Serrels B, Lietha D, Eck MJ. The FERM domain: Organizing the structure and function of FAK. Nat Rev Mol Cell Biol 2010; 11:802-814.
29. Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S. Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic Biol Med 2008; 45:1403-1412.
30. 2+ and the activation of caspase-3. Anticancer Res 2006; 26:4379-4389.
31. Hu H, Li GX, Wang L, et al. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 2008; 14:1150-1158.
32. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275:38953-38956.
33. Van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10:389-399.
34. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10:375-388.
35. Kobayashi S, Lee SH, Meng XW, et al. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem 2007; 282:18407-18417.
36. Hu H, Chai Y, Wang L, et al. Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells. Mol Cancer Ther 2009; 8:2833-2843.
37. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71:1397-1421.
38. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009; 15:1250-1258.
39. Cheng CY, Lin YH, Su CC. Curcumin inhibits the proliferation of human hepatocellular carcinoma J5 cells by inducing endoplasmic reticulum stress and mitochondrial dysfunction. Int J Mol Med 2010; 26:673-678.
40. Van Nimwegen MJ, Van de Water B. Focal adhesion kinase: A potential target in cancer therapy. Biochem Pharmacol 2007; 73:597-609.
41. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134:793-799.
42. Leu TH, Su SL, Chuang YC, Maa MC. Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem Pharmacol 2003; 66:2323-2331.